PD-L1-expressing Regulatory T Cells in Localized Prostate Cancer Patients Undergoing Iodine-125 Permanent Brachytherapy
Status
Conditions
Treatments
Details and patient eligibility
About
Immunotherapy is currently revolutionizing the field in oncology. However, prostate cancer is poorly responsive to immune checkpoint inhibition. The combination of immunotherapy and radiotherapy is an emerging clinical treatment aradigm. X-ray radiation treatment can activate both the adaptive and innate immune systems through directly killing tumor cells, causing mutations in tumor-derived peptides, and causing localized inflammation that increases immune cell trafficking to tumors. Recently, preclinical study reported that immune checkpoint inhibition combined with radiotherapy treats CPRC with significant increases in median survival compared to drug alone.
Full description
Permanent brachytherapy is one of those standard treatments for localized prostate cancer patients.
Biopsy confirms prostate cancer. Blood and urine of localized prostate cancer patients will be collected before and at different time points after permanent brachytherapy (1, 3, 6, and 12 months)
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Biopsy confirms prostate cancer
Localized Prostate Cancer, ≤cT3
No chemotherapy or Hormonal therapy before Permanent Brachytherapy
Exclusion criteria
- Unacceptable operative risk
Poor anatomy which in the opinion of the radiation oncologist could lead to a suboptimal implant (e.g.,large or poorly healed transurethral resection of the prostate (TURP) defect, large median lobe, large gland size).
Pathologically positive lymph nodes
Significant obstructive uropathy
Distant metastases
Use steroids regularly
The diagnosis was accompanied by immune-related diseases
Allergic constitution
Abnormal white blood cell and lymphocyte counts
Ever underwent other treatments for prostate cancer, such as chemotherapy or Hormonal therapy
Accompanied by other malignancies
Splenectomy
HIV positive
Receive an anti-infective vaccine for the last 6 months
Trial contacts and locations
Loading...
Central trial contact
Tongwen Ou, MD.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal